{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:03:04Z","timestamp":1789736584367,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hebei Provincial Administration of Traditional Chinese Medi-cine Project","award":["2026472"],"award-info":[{"award-number":["2026472"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02161-6","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:06:04Z","timestamp":1789733164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IER5L Facilitates the Progression of Hormone Receptor-Positive Breast Cancer by Inhibiting HSF1 Phosphorylation in Response to Bevacizumab"],"prefix":"10.1007","author":[{"given":"Wei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4889-4400","authenticated-orcid":false,"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2161_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M., et al. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast, 66, 15\u201323.","journal-title":"Breast"},{"issue":"20","key":"2161_CR2","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke, H., et al. (2010). Metastatic behavior of breast cancer subtypes. Journal Of Clinical Oncology, 28(20), 3271\u20133277.","journal-title":"Journal Of Clinical Oncology"},{"issue":"10","key":"2161_CR3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc, K. D., et al. (2010). Breast cancer subtypes and the risk of local and regional relapse. Journal Of Clinical Oncology, 28(10), 1684\u20131691.","journal-title":"Journal Of Clinical Oncology"},{"issue":"3","key":"2161_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-014-3112-6","volume":"147","author":"L Chen","year":"2014","unstructured":"Chen, L., et al. (2014). Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Research And Treatment, 147(3), 609\u2013616.","journal-title":"Breast Cancer Research And Treatment"},{"key":"2161_CR5","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.2147\/IJGM.S439190","volume":"16","author":"X Chen","year":"2023","unstructured":"Chen, X., et al. (2023). IER5L is a Prognostic Biomarker in Pan-Cancer Analysis and Correlates with Immune Infiltration and Immune Molecules in Non-Small Cell Lung Cancer. International Journal Of General Medicine, 16, 5889\u20135908.","journal-title":"International Journal Of General Medicine"},{"issue":"7","key":"2161_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41419-024-06907-z","volume":"15","author":"JR Crespo","year":"2024","unstructured":"Crespo, J. R., et al. (2024). The PP2A regulator IER5L supports prostate cancer progression. Cell Death And Disease, 15(7), 514.","journal-title":"Cell Death And Disease"},{"issue":"7","key":"2161_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2174\/1568009618666181018162117","volume":"19","author":"RL Carpenter","year":"2019","unstructured":"Carpenter, R. L., & G\u00f6kmen-Polar, Y. (2019). HSF1 as a Cancer Biomarker and Therapeutic Target. Current Cancer Drug Targets, 19(7), 515\u2013524.","journal-title":"Current Cancer Drug Targets"},{"issue":"7","key":"2161_CR8","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.7150\/thno.82431","volume":"13","author":"Y Chin","year":"2023","unstructured":"Chin, Y., et al. (2023). Targeting HSF1 for cancer treatment: mechanisms and inhibitor development. Theranostics, 13(7), 2281\u20132300.","journal-title":"Theranostics"},{"issue":"51","key":"2161_CR9","doi-asserted-by":"publisher","first-page":"84239","DOI":"10.18632\/oncotarget.12438","volume":"7","author":"Y G\u00f6kmen-Polar","year":"2016","unstructured":"G\u00f6kmen-Polar, Y., & Badve, S. (2016). Upregulation of HSF1 in estrogen receptor positive breast cancer. Oncotarget, 7(51), 84239\u201384245.","journal-title":"Oncotarget"},{"issue":"45","key":"2161_CR10","doi-asserted-by":"publisher","first-page":"18378","DOI":"10.1073\/pnas.1115031108","volume":"108","author":"S Santagata","year":"2011","unstructured":"Santagata, S., et al. (2011). High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A, 108(45), 18378\u201318383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2161_CR11","doi-asserted-by":"crossref","unstructured":"Vydra, N. (2021). Heat shock factor 1 (HSF1) cooperates with estrogen receptor \u03b1 (ER\u03b1) in the regulation of estrogen action in breast cancer cells. Elife, 10.","DOI":"10.7554\/eLife.69843"},{"issue":"5","key":"2161_CR12","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1111\/jcmm.14243","volume":"23","author":"W Yang","year":"2019","unstructured":"Yang, W., et al. (2019). FAM3C-YY1 axis is essential for TGF\u03b2-promoted proliferation and migration of human breast cancer MDA-MB-231 cells via the activation of HSF1. Journal Of Cellular And Molecular Medicine, 23(5), 3464\u20133475.","journal-title":"Journal Of Cellular And Molecular Medicine"},{"key":"2161_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cellsig.2018.12.012","volume":"55","author":"T Ueda","year":"2019","unstructured":"Ueda, T., et al. (2019). IER family proteins are regulators of protein phosphatase PP2A and modulate the phosphorylation status of CDC25A. Cellular Signalling, 55, 81\u201389.","journal-title":"Cellular Signalling"},{"issue":"2","key":"2161_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41416-023-02509-2","volume":"130","author":"SA Patel","year":"2024","unstructured":"Patel, S. A., et al. (2024). EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia. British Journal Of Cancer, 130(2), 184\u2013200.","journal-title":"British Journal Of Cancer"},{"issue":"24","key":"2161_CR15","doi-asserted-by":"publisher","first-page":"e2307639","DOI":"10.1002\/advs.202307639","volume":"11","author":"T Jin","year":"2024","unstructured":"Jin, T., et al. (2024). HnRNPA2B1 ISGylation Regulates m6A-Tagged mRNA Selective Export via ALYREF\/NXF1 Complex to Foster Breast Cancer Development. Adv Sci (Weinh), 11(24), e2307639.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"2161_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-020-05955-1","volume":"185","author":"YA Kariri","year":"2021","unstructured":"Kariri, Y. A., et al. (2021). The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. Breast Cancer Research And Treatment, 185(2), 293\u2013305.","journal-title":"Breast Cancer Research And Treatment"},{"key":"2161_CR17","doi-asserted-by":"crossref","unstructured":"Zhao, X. (2022). GDF15 Contributes to Radioresistance by Mediating the EMT and Stemness of Breast Cancer Cells. Int J Mol Sci, 23(18).","DOI":"10.3390\/ijms231810911"},{"issue":"Pt 18","key":"2161_CR18","first-page":"3893","volume":"127","author":"IR Macpherson","year":"2014","unstructured":"Macpherson, I. R., et al. (2014). CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal Of Cell Science, 127(Pt 18), 3893\u20133901.","journal-title":"Journal Of Cell Science"},{"issue":"9","key":"2161_CR19","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/14712598.2012.704015","volume":"12","author":"AC Small","year":"2012","unstructured":"Small, A. C., & Oh, W. K. (2012). Bevacizumab treatment of prostate cancer. Expert Opinion On Biological Therapy, 12(9), 1241\u20131249.","journal-title":"Expert Opinion On Biological Therapy"},{"issue":"3","key":"2161_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/14712598.2016.1145208","volume":"16","author":"N Bizzarri","year":"2016","unstructured":"Bizzarri, N., et al. (2016). Bevacizumab for the treatment of cervical cancer. Expert Opinion On Biological Therapy, 16(3), 407\u2013419.","journal-title":"Expert Opinion On Biological Therapy"},{"key":"2161_CR21","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.2147\/DDDT.S83275","volume":"9","author":"H Yoshida","year":"2015","unstructured":"Yoshida, H., et al. (2015). Critical appraisal of bevacizumab in the treatment of ovarian cancer. Drug Design, Development And Therapy, 9, 2351\u20132358.","journal-title":"Drug Design, Development And Therapy"},{"issue":"5","key":"2161_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1753465816652083","volume":"10","author":"L Greillier","year":"2016","unstructured":"Greillier, L., et al. (2016). Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. Therapeutic Advances In Respiratory Disease, 10(5), 485\u2013491.","journal-title":"Therapeutic Advances In Respiratory Disease"},{"key":"2161_CR23","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J., et al. (2020). Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews, 86, 102017.","journal-title":"Cancer Treatment Reviews"},{"issue":"2","key":"2161_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.hoc.2007.03.006","volume":"21","author":"TA Traina","year":"2007","unstructured":"Traina, T. A., et al. (2007). Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am, 21(2), 303\u2013319.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2161_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.seminoncol.2017.10.010","volume":"44","author":"L Varella","year":"2017","unstructured":"Varella, L., et al. (2017). Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer. Seminars In Oncology, 44(4), 273\u2013285.","journal-title":"Seminars In Oncology"},{"key":"2161_CR26","doi-asserted-by":"publisher","first-page":"955984","DOI":"10.3389\/fphar.2022.955984","volume":"13","author":"Y Fan","year":"2022","unstructured":"Fan, Y., et al. (2022). Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44\/CD117 in human ovarian cancer SKOV3 cells. Frontiers In Pharmacology, 13, 955984.","journal-title":"Frontiers In Pharmacology"},{"issue":"18","key":"2161_CR27","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.7150\/jca.24201","volume":"9","author":"Z Zhao","year":"2018","unstructured":"Zhao, Z., et al. (2018). Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells. Journal Of Cancer, 9(18), 3407\u20133416.","journal-title":"Journal Of Cancer"},{"issue":"15","key":"2161_CR28","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.3390\/cancers13153668","volume":"13","author":"A Alonso-Diez","year":"2021","unstructured":"Alonso-Diez, A. (2021). Anti-angiogenic treatments interact with steroid secretion in inflammatory breast cancer triple negative cell lines. Cancers (Basel), 13(15), 3668.","journal-title":"Cancers (Basel)"},{"key":"2161_CR29","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.ctrv.2024.102861","volume":"132","author":"C Hao","year":"2025","unstructured":"Hao, C., et al. (2025). PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treatment Reviews, 132, 102861.","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"2161_CR30","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne, I. M., et al. (2024). Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. The Lancet Oncology, 25(4), e139\u2013e151.","journal-title":"The Lancet Oncology"},{"issue":"8","key":"2161_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nrm2938","volume":"11","author":"M Akerfelt","year":"2010","unstructured":"Akerfelt, M., et al. (2010). Heat shock factors: integrators of cell stress, development and lifespan. Nature Reviews Molecular Cell Biology, 11(8), 545\u2013555.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"8\u20139","key":"2161_CR32","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1007\/PL00000757","volume":"57","author":"AJ Whitmarsh","year":"2000","unstructured":"Whitmarsh, A. J., & Davis, R. J. (2000). Regulation of transcription factor function by phosphorylation. Cellular And Molecular Life Sciences, 57(8\u20139), 1172\u20131183.","journal-title":"Cellular And Molecular Life Sciences"},{"issue":"5","key":"2161_CR33","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1021\/pr201151a","volume":"11","author":"YM Xu","year":"2012","unstructured":"Xu, Y. M., et al. (2012). Post-translational modification of human heat shock factors and their functions: a recent update by proteomic approach. Journal Of Proteome Research, 11(5), 2625\u20132634.","journal-title":"Journal Of Proteome Research"},{"issue":"5","key":"2161_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cac2.12284","volume":"42","author":"M Huang","year":"2022","unstructured":"Huang, M., et al. (2022). HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program. Cancer Commun (Lond), 42(5), 447\u2013470.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"2161_CR35","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-022-32034-4","volume":"13","author":"M Fujimoto","year":"2022","unstructured":"Fujimoto, M., et al. (2022). HSF1 phosphorylation establishes an active chromatin state via the TRRAP-TIP60 complex and promotes tumorigenesis. Nature Communications, 13(1), 4355.","journal-title":"Nature Communications"},{"issue":"1","key":"2161_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nrm.2017.73","volume":"19","author":"R Gomez-Pastor","year":"2017","unstructured":"Gomez-Pastor, R. et al. (2017). Regulation of heat shock transcription factors and their roles in physiology and disease. Nature Reviews Molecular Cell Biology, 19(1), 4\u201319.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"2","key":"2161_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1568009614666140122155942","volume":"14","author":"N Vydra","year":"2014","unstructured":"Vydra, N., et al. (2014). Pleiotropic role of HSF1 in neoplastic transformation. Current Cancer Drug Targets, 14(2), 144\u2013155.","journal-title":"Current Cancer Drug Targets"},{"issue":"5","key":"2161_CR38","doi-asserted-by":"publisher","first-page":"e202000811","DOI":"10.26508\/lsa.202000811","volume":"4","author":"MA Silveira","year":"2021","unstructured":"Silveira, M. A. et al. (2021). Modulating HSF1 levels impacts expression of the estrogen receptor \u03b1 and antiestrogen response. Life Sci Alliance, 4(5), e202000811.","journal-title":"Life Sci Alliance"},{"issue":"1","key":"2161_CR39","doi-asserted-by":"publisher","first-page":"BSR20222102","DOI":"10.1042\/BSR20222102","volume":"43","author":"V Tandon","year":"2023","unstructured":"Tandon, V., et al. (2023). Dual inhibition of HSF1 and DYRK2 impedes cancer progression. Bioscience Reports, 43(1), BSR20222102.","journal-title":"Bioscience Reports"},{"issue":"Pt 24","key":"2161_CR40","first-page":"5273","volume":"127","author":"N Benderska","year":"2014","unstructured":"Benderska, N., et al. (2014). DAPK-HSF1 interaction as a positive-feedback mechanism stimulating TNF-induced apoptosis in colorectal cancer cells. Journal Of Cell Science, 127(Pt 24), 5273\u20135287.","journal-title":"Journal Of Cell Science"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02161-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02161-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:06:08Z","timestamp":1789733168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02161-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":40,"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02161-6","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"18 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}